Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes
Possible immunogenicity of the Cas9 protein raises concerns about therapeutic applications. Here the authors identify pre-existing CD8+T-cell immunity in healthy individuals and in response modify Cas9 to remove the immunodominant epitopes.
Guardado en:
Autores principales: | Shayesteh R. Ferdosi, Radwa Ewaisha, Farzaneh Moghadam, Sri Krishna, Jin G. Park, Mo R. Ebrahimkhani, Samira Kiani, Karen S. Anderson |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7163fcf8bec84bbaa28f45dd3cb383d7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
CRISPR/Cas9 in Gastrointestinal Malignancies
por: André Jefremow, et al.
Publicado: (2021) -
Optimized design parameters for CRISPR Cas9 and Cas12a homology-directed repair
por: Mollie S. Schubert, et al.
Publicado: (2021) -
Chromosome drives via CRISPR-Cas9 in yeast
por: Hui Xu, et al.
Publicado: (2020) -
Inhibition of CRISPR-Cas9 ribonucleoprotein complex assembly by anti-CRISPR AcrIIC2
por: Annoj Thavalingam, et al.
Publicado: (2019) -
A catalogue of biochemically diverse CRISPR-Cas9 orthologs
por: Giedrius Gasiunas, et al.
Publicado: (2020)